Rofecoxib (162011-90-7) is a potent and selective COX-2 inhibitor with 1000-fold selectivity over COX-1, IC50=26 nm vs >50 μM1. Potent nonsteroidal anti-inflammatory agent1. Rofecoxib is a clinically useful NSAID which was withdrawn from use due to cardiovascular side effects3.
1) Chan et al. (1999), Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles; J. Pharmacol. Exp. Ther., 290 551
2) Catalla-Lawson et al. (2013), Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamnics and vasoactive eicosanoids; J. Pharmacol. Exp. Ther., 289 735